Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00793013
Other study ID # 123456789
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date November 2, 2020
Est. completion date November 2, 2020

Study information

Verified date November 2020
Source University of Tennessee, Chattanooga
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Traditional modes of ventilation have failed to improve patient survival. Subsequent observations that elevated airway pressures observed in traditional forms of ventilation resulted in barotrauma and extension of ALI lead to the evolution of low volume cycled ventilation as a potentially better ventilatory modality for ARDS. Recent multicenter trials by the NIH-ARDS network have confirmed that low volume ventilation increases the number of ventilatory free days and improves overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.


Description:

Low volume ventilation may increase number of ventilatory free days and may improve overall patient survival. While reducing mean airway pressure has reduced barotrauma and improved patient survival, it has impaired attempts to improve alveolar recruitment. Alveolar recruitment is important as it improves V/Q mismatch, allows reduction in FIO2 earlier, and decreases the risk of oxygen toxicity. Airway pressure release ventilation (APRV) is a novel ventilatory modality that utilizes controlled positive airway pressure to maximize alveolar recruitment while minimizing barotrauma. In APRV, tidal ventilation occurs between the increase in lung volumes established by the application of CPAP and the relaxation of lung tissue following pressure release. Preliminary studies have suggested that APRV recruits collapsed alveoli and improves oxygenation through a restoration of pulmonary mechanics, but there are no studies indicating the potential overall benefit of APRV in recovery form ALI/ADRS.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2, 2020
Est. primary completion date November 2, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - All patients admitted to the Internal Medicine service at the Baroness Erlanger Hospital of the University of Tennessee College of Medicine with hypoxia (O2 saturation < 93%) and pulmonary distress, will be screened for study participation. - Patients displaying all the following clinical criteria: acute onset of respiratory failure; hypoxia defined as a PaO2/FiO2 ratio of < 300 Torr; pulmonary capillary wedge pressure less or equal than 18 mm Hg, and/or no clinical evidence of left sided heart failure; and chest x-ray with diffuse bilateral pulmonary infiltrates. Exclusion Criteria: - Patients receiving conventional volume ventilation with or without PEEP for > 6 hours prior to study enrollment - Patient's family or surrogate unwilling to give informed consent - Patients requiring sedation or paralysis for effective ventilation - Patients known pulmonary embolus within 72 hours of study enrollment - Patients with close head injuries or evidence of increased intracranial pressure - Patients with burns over 30% of total body surface area - Pulmonary capillary wedge pressure greater than 18 mm Hg - CVP > 15 cm H2O - Patients with B type Naturetic peptide levels > 1000 - Patients with prior history of dilated cardiomyopathy with EF < 25% - Patients receiving chronic outpatient peritoneal or hemodialysis - Patients with severe liver disease (as defined by Child-Pugh class C) - AIDS patients

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Volume-Cycled Assist-Control (AC) mode
Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40% Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2 Inspiratory to Expiratory ratio set at 1:1 to 1:3 If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased Mgmt of PEEP will be conducted as per the ARDSnet Protocol Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95% Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol
Airway Pressure Release Ventilation (APRV) mode
Ventilation uses Drager Model X1 Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels Time periods for the high & low pressure levels can be set independently Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min Spontaneous frequency will be targeted for 6 to 18 breaths/per min If spontaneous breathing is achieved,level of sedation will be decreased If spontaneous respirations are >20 breaths/min, sedation will be increased If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased

Locations

Country Name City State
United States James A. Tumlin, MD Chattanooga Tennessee

Sponsors (1)

Lead Sponsor Collaborator
University of Tennessee, Chattanooga

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary All cause mortality 28 days or prior to hospital discharge
Secondary Number of ventilator-free days 28 days or prior to hospital discarge
Secondary Length of ICU stay and /or Total hospital days 28 days or prior to hospital discharge
Secondary To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the incidence of of AKI 28 days or prior to hospital discharge
Secondary To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation on the NGAL, KIM-1, and IL-18 urine biomarkers for AKI 28 days or prior to hospital discharge
Secondary To determine the effects of APRV ventilation versus ARDS net low volume-cycle ventilation in maintaining hourly urine output > 0.5 mls/kg/hr 28 days or prior to hospital discharge
Secondary Will determine urinary aquaporin-2 levels in patients randomized to APRV ventilation versus ARDS net low volume-cycle ventilation 28 days or prior to hospital discharge
See also
  Status Clinical Trial Phase
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04247477 - Comparison of Different PEEP Titration Strategies Using Electrical Impedance Tomography in Patients With ARDS N/A
Completed NCT03315702 - Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins
Not yet recruiting NCT02693912 - Changes in Alveolar Macrophage Function During Acute Lung Injury N/A
Completed NCT01659307 - The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury Phase 2
Completed NCT01552070 - Recruitment on Extravascular Lung Water in Acute Respiratory Distress Syndrome (ARDS) Phase 2
Unknown status NCT01186874 - Epidemiology Research on Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) in Adult ICU in Shanghai N/A
Withdrawn NCT00961168 - Work of Breathing and Mechanical Ventilation in Acute Lung Injury N/A
Recruiting NCT00759590 - Comparison of Two Methods to Estimate the Lung Recruitment N/A
Completed NCT00736892 - Incidence of Acute Lung Injury: The Alien Study
Completed NCT02475694 - Acute Lung Injury After Cardiac Surgery: Pathogenesis N/A
Completed NCT00825357 - Biological Markers to Identify Early Sepsis and Acute Lung Injury N/A
Terminated NCT00263146 - Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers. N/A
Completed NCT00188058 - Comparison of 2 Strategies of Adjustment of Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome N/A
Completed NCT00234767 - Study of the Economics of Pulmonary Artery Catheter Use in Patients With Acute Respiratory Distress Syndrome (ARDS) Phase 3
Recruiting NCT02598648 - Role and Molecular Mechanism of Farnesoid X Receptor(FXR) and RIPK3 in the Formation of Acute Respiratory Distress Syndrome in Neonates N/A
Recruiting NCT02948530 - Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods (Lungbarometry)
Completed NCT01532024 - Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs Early Phase 1
Recruiting NCT01992237 - Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients N/A
Completed NCT01486342 - PET Imaging in Patients at Risk for Acute Lung Injury N/A